PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.

J Neurooncol · 2025 · PMC12263475 · PMID 40504311

Europe PMC DOI

hedged sentences

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significancep = 0.075so close (0.05 < p ≤ 0.1)

Although survival tended to be longer in the PIK3R2-negative subgroup of the AFTV group compared to the corresponding control group, this difference did not reach statistical significance (log-rank test, p = 0.075).

also in 111,027 other papers

showed a trendno p-value reported

Among patients with GBM, the p53-negative subgroup in the AFTV group showed a trend toward improved survival (65.6 months mOS) compared to the same subgroup in the control group (35.8 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.